When was BioAmp Diagnostics founded?

BioAmp Diagnostics was founded in 2017 and raised its 1st funding round within a year of its incorporation.

Where is BioAmp Diagnostics located?

BioAmp Diagnostics is headquartered in Berkeley, United States.

How many employees does BioAmp Diagnostics have?

As of Aug 31, 2026, the latest employee count at BioAmp Diagnostics is 7.

Is BioAmp Diagnostics a funded company?

BioAmp Diagnostics is a funded company, having raised an undisclosed amount across 7 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2017.

When was the latest funding round of BioAmp Diagnostics?

BioAmp Diagnostics' latest funding was a $***** Grant (prize money) round on Aug 05, 2025, with participation from 1 investor. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $1.3B in funding in 2026 to date.

Where does BioAmp Diagnostics rank among its competitors?

BioAmp Diagnostics ranks 4th amongst 17 active competitors, of which 6 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Haga Bio Science, which secured $2.3M in Jun, 2026.

Who are the top competitors of BioAmp Diagnostics?

BioAmp Diagnostics' top competitors include Araceli Biosciences, ACD and Lodestone Biomedical. Among them, Haga Bio Science secured the most recent funding round in June, 2026.

BioAmp Diagnostics - 2026 Company Profile, Team, Funding & Competitors

BioAmp Diagnostics is a seed company based in Berkeley (United States), founded in 2017 by Tara Deboer and Nicole Tarlton. It operates as a Developers of diagnostic tests that help to treat patient with a specific antibiotic. BioAmp Diagnostics has raised an undisclosed amount in funding from Illumina and CITRIS Foundry. The company has 17 active competitors, including 6 funded and 1 that has exited. Its top competitors include companies like Araceli Biosciences, ACD and Lodestone Biomedical.

Company Details

BioAmp is the developers of diagnostic tests that help to treat patients with a specific antibiotic. They identify the target biomarkers of resistance directly in patient samples. This helps the physician to prescribe the appropriate antibiotic for the first time only.

Website: bioampdx.com
Social

Key Metrics

Founded Year

2017

Location

Berkeley, United States

Stage

Seed

Latest Funding Round

Grant (prize money), Aug 05, 2025, $*****

Investors

Illumina & 9 more

Ranked

4^th among 17 active competitors

Employee Count

7 as on Aug 31, 2026

Similar Companies

Araceli Biosciences & 18 more

View BioAmp Diagnostics' full profile

BioAmp Diagnostics has raised funding over 7 rounds. Its first funding round was on 2017. Its latest funding round was a Grant (prize money) round on Aug 05, 2025 for $*****. 1 investor participated in its latest round. BioAmp Diagnostics has 10 institutional investors.

Here is the list of recent funding rounds of BioAmp Diagnostics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 05, 2025	4782625	Grant (prize money)	5702009	4396493	4670881	5312265
Mar 27, 2025	5640276	Grant (prize money)	2320759	8430961	9837371	HHS
Apr 02, 2024	5604797	Grant (prize money)	2748498	5214140	5331102	National Science Foundation

Access funding benchmarks and valuations. Sign up today!

View details of BioAmp Diagnostics's funding rounds and investors

The founders of BioAmp Diagnostics are Tara Deboer and Nicole Tarlton.

Here are the details of BioAmp Diagnostics' key team members:

Tara Deboer: Co-Founder of BioAmp Diagnostics and founder of 1 other company.
Contact Info: 1 email address
Nicole Tarlton: Co-Founder of BioAmp Diagnostics.

View details of BioAmp Diagnostics's Founder profiles and Board Members

BioAmp Diagnostics' employee count trend

BioAmp Diagnostics has 7 employees as of Aug 26. Here is BioAmp Diagnostics's employee count trend over the years:

Employee count trend for BioAmp Diagnostics

Uncover BioAmp Diagnostics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of BioAmp Diagnostics include Araceli Biosciences, ACD and Lodestone Biomedical. Here is the list of Top 10 competitors of BioAmp Diagnostics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Araceli Biosciences 2020, United States, Seed	Developer of scientific tools for tissue and cell-based biomarker discovery & drug development	$25.7M	-	53/100
2nd	ACD 2006, Newark (United States), Acquired	Developer of a transnational research platform for biomarker analysis	$39.4M	Summit Partners, Morningside & 5 others	52/100
3rd	Lodestone Biomedical 2015, Hanover (United States), Seed	Provider of magnetic nanoparticle platform technology for in vivo biomarker monitoring in immuno-oncology	$1.18M	MassChallenge, Dartmouth Regional Technology Center ... Read more	41/100
4th	BioAmp Diagnostics 2017, Berkeley (United States), Seed	Developers of diagnostic tests that help to treat patient with a specific antibiotic	-	Illumina, R42 Group & 8 others	35/100
5th	BioImage 1999, Copenhagen (Denmark), Acqui-Hired	Developer of bioassays for biopharmaceutical companies and research institutions	$30.5M	Abingworth, Novo Holdings & 3 others	32/100
6th	HAWK Biosystems 2015, Derio (Spain), Seed	Developer of clinical assays for quantifying novel biomarkers	-	EIC Fund, Europa	30/100
7th	Haga Bio Science Solna (Sweden), Seed	Developer of spatial RNA detection assays for clinical biomarker validation	$2.3M	Almi Invest, Life Science Invest	27/100
8th	Fyr Missoula (United States), Unfunded	Provider of extracellular vesicle omics platform for precision medicine advancement	-	-	25/100
9th	ACS Biomarker 2007, Maastricht (Netherlands), Series A	ACS Biomarker is a Dutch biotechnology company focusing on the discovery, validation and commercialization of novel biomarkers for cardiac disease.	-	Brightlands Venture Partners, Life Sciences Fund Amsterdam ... & 3 others	24/100
10th	Genosaber 2010, Shanghai (China), Funding Raised	Diagnostic tools to detect the presence of circulating tumor cells.	-	Infinity Group	24/100